AbbVie has announced that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.

Nimble's lead asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis. Additionally, Nimble's peptide synthesis, screening, and optimisation platform uses proprietary technology to help drive rapid discovery and optimisation of oral peptide candidates for a range of targets.

Commenting on the development, Jonathon Sedgwick, Senior Vice President and Global Head of Discovery Research, AbbVie said, “With the acquisition now complete, we are excited to expand our immunology pipeline to include Nimble's novel oral peptide assets and look forward to integrating this proprietary technology into our R&D capabilities. We are pleased to welcome the talented team at Nimble who share our commitment to elevating the standard of care for people living with autoimmune diseases.”